Recently, in a clinical phase Ib study, patients with lung cancer and resistance to therapy with erlotinib and gefitinib showed a clinical benefit from sequential treatment, that is, after progression under therapy with the anti-EGFR TKI afatinib, they profited from the combined therapy with afatinib and cetuximab [35]. This evidence concerns the gene EGFR and lung carcinoma.